BRAF and Miyoshi myopathy: In this regard, oncogenic mutations in c-KIT, NRAS, and BRAF components of the MAPK pathway have been identified in nearly 90% of cutaneous MM [3]; in particular, BRAF and NRAS mutations are the most frequently observed [4].